Clinical trialNCT01644253TerminatedPhase 1Interventional

Phase 1b Safety and Efficacy Study of TRU-016

SponsorAptevo TherapeuticsEnrollment87Chronic Lymphocytic LeukemiaPeripheral T-cell Lymphoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to evaluate the efficacy and safety of TRU-016 in combination with rituximab, in combination with obinutuzumab, in combination with rituximab and idelalisib, or in combination with ibrutinib in patients with CLL; and in combination with bendamustine in patients with PTCL.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Scott C. Stromatt, M.D.
Aptevo Therapeutics
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Facility name not stated
Augusta, Georgia, United States
Facility name not stated
Columbus, Ohio, United States
Eastern Regional Medical Center
Philadelphia, Pennsylvania, United States
University of Pittsburgh
Pittsburgh, Pennsylvania, United States
Greenville Health System
Greenville, South Carolina, United States
Facility name not stated
Houston, Texas, United States
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
Swedish Cancer Institute,1221 Madison St.
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

10 mg/kg TRU-016 + Rituximab20 mg/kg TRU-016 + RituximabTRU-016 10-20 mg/kg + bendamustineTRU-016 10-20 mg/kg + ibrutinibTRU-016 20 mg/kg + ObinutuzumabTRU-016 6-20 mg/kg + idelalisib + rituximab

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Sept 2012
Primary completion: 24 Feb 2020
Completion: 21 Apr 2021
Last update posted: 20 May 2021
Registered enrollment: 87
Registry id: NCT01644253

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.